ReviewFrontiers in oncology2014
Animal models in osteosarcoma.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy.Science advances · 2026Article
- Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026Review
- An improved experimental model of osteosarcoma lung metastases to investigate innovative therapeutic interventions and sex as a biological variable.International journal of pharmaceutics · 2025Article
- Alterations in Serum Lipids and Lipoproteins Induced by Neoadjuvant Chemotherapy in Patients with Osteosarcoma around the Knee Joint: A Retrospective Analysis.Current medical science · 2024Article
- The generation and use of animal models of osteosarcoma in cancer research.Genes & diseases · 2024Review
- Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature.Frontiers in molecular biosciences · 2024Review
- Dog breeds and conformations predisposed to osteosarcoma in the UK: a VetCompass study.Canine medicine and genetics · 2023Article
- Fabrication of a composite 3D-printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence.Materials today. Bio · 2023Article
- NOTCH Signaling in Osteosarcoma.Current issues in molecular biology · 2023Review
- A 3D-printed scaffold-based osteosarcoma model allows to investigate tumor phenotypes and pathogenesis in an in vitro bone-mimicking niche.Materials today. Bio · 2022Article
- Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model.Pharmaceutics · 2022Article
- Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma.Acta veterinaria Scandinavica · 2021Article
- Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.Pediatric blood & cancer · 2021Article
- Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma.Experimental and therapeutic medicine · 2021Article
- Research models and mesenchymal/epithelial plasticity of osteosarcoma.Cell & bioscience · 2021Review
- Allelic Expression Imbalance Analysis IdentifiedCancers · 2021Article
- Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study.Canine medicine and genetics · 2021Article
- Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2021Article
- Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA.Oncogene · 2021Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is the most common non-hematologic primary tumor of bone in children and adults. High-dose cytotoxic chemotherapy and surgical resection have improved prognosis, with long-term survival for non-metastatic disease approaching 70%. However, most OS tumors are high grade and tend to rapidly develop pulmonary metastases. Despite clinical advances, patients with metastatic disease or relapse have a poor prognosis. Toward a better understanding of the molecular pathogenesis of human OS, several genetically modified OS mouse models have been developed and will be reviewed here. However, better animal models that more accurately recapitulate the natural progression of the disease are needed for the development of improved prognostic and diagnostic markers as well as targeted therapies for both primary and metastatic OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.